Verition Fund Management
EIGR

Verition Fund Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Verition Fund Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,806
Closed -$12.2K – 3036
2023
Q4 		$12.2K Sell
1,806
-277
-13% -$2.44K ﹤0.01% 2223
2023
Q3 		$19.1K Sell
2,083
-2,917
-58% -$58.7K ﹤0.01% 2225
2023
Q2 		$106K Buy
+5,000
New +$154K ﹤0.01% 1969

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Verition Fund Management's EIGR Position: Q1 2024 in Review

Verition Fund Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 1,806 shares — an estimated $12.2K sold.

Verition Fund Management first reported a position in EIGR in Q2 2023 and held it in 3 quarters. The position peaked at $106K in Q2 2023. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Verition Fund Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Verition Fund Management sold 1,806 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $12.2K.
  • Verition Fund Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 3 quarters.
  • Verition Fund Management's Eiger BioPharmaceuticals, Inc. position peaked at $106K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.